RFK Jr.'s handpicked committee approves manufacture of peptides he uses

RFK Jr.’s newly appointed FDA advisory committee members voted to overturn limits on compounding certain unapproved peptides.

The decision came despite limited clinical safety data and opposition from the committee’s pre-existing members.

If adopted, the move could broaden access to these compounded peptide drugs.

It may also intensify tensions between FDA scientists and Kennedy over drug regulation and agency authority.